Severe acute respiratory syndrome coronavirus 2 has had an indelible effect, with 153,738,171 cases recorded globally as per the World Health Organization's dashboard. The medical establishment is racing to find repurposed medications that can be successful against this novel coronavirus due to a shortage of new drugs to treat the disease. Favipiravir, an antiviral drug originally developed for influenza, is one of the drugs that has recently received a lot of attention, particularly in India. Here, we present a case of favipiravir-induced drug fever in a young adult coronavirus disease 2019 patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189533 | PMC |
| http://dx.doi.org/10.7759/cureus.14928 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alleviation of favipiravir-induced hepatotoxicity using hepatoprotective herbal extracts in wistar rats.
Nat Prod Res
August 2024
Innovation and Drug Discovery Team, Sava Healthcare Limited, Research Center, MIDC, Pune, India.
Teratogenicity and hyperuricaemia are the main side effects of favipiravir, an antiviral drug recently found its use to treat mild to moderate coronavirus (COVID-19) infections. This study investigated the beneficial effect of herbal extracts like (PK) and (SB) and their active chemical constituents (baicalin and baicalein) on favipiravir-induced hepatotoxicity in rats. The formulation combinations included favipiravir, favipiravir + PK extract, favipiravir + pure baicalin, favipiravir + pure baicalein, and favipiravir + SB extract designated as F1, F2, F3, F4 and F5 respectively that were administered to rats orally for 21 days.
View Article and Find Full Text PDFFavipiravir-induced bradycardia: A case report.
Clin Case Rep
July 2024
Department of Cardiology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Key Clinical Message: The purpose of this case report is to reveal one of the cardiovascular side effects of favipiravir, sinus bradycardia.
Abstract: Favipiravir has emerged as a potential treatment for COVID-19, with its antiviral properties showing promise in inhibiting viral replication. However, concerns regarding its safety profile, particularly its cardiac adverse effects, remain a subject of debate.
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients.
Clin Immunol
February 2024
Infection, Immunity and Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Institute of Immunity and Transplantation, University College London, London, UK. Electronic address:
Chronic human norovirus (HuNoV) infections in immunocompromised patients result in severe disease, yet approved antivirals are lacking. RNA-dependent RNA polymerase (RdRp) inhibitors inducing viral mutagenesis display broad-spectrum in vitro antiviral activity, but clinical efficacy in HuNoV infections is anecdotal and the potential emergence of drug-resistant variants is concerning. Upon favipiravir (and nitazoxanide) treatment of four immunocompromised patients with life-threatening HuNoV infections, viral whole-genome sequencing showed accumulation of favipiravir-induced mutations which coincided with clinical improvement although treatment failed to clear HuNoV.
View Article and Find Full Text PDFFollow-up of Favipiravir-Induced Nail Fluorescence: Implications for Nail and Drugs.
Dermatol Pract Concept
January 2023
Department of Pharmacology, Medical Faculty, Maltepe University, Istanbul, Turkey.
Introduction: Favipiravir creates fluorescence on nails, which can be seen with Wood's light.
Objectives: The objectives of this study are to examine the properties of fluorescence in the nail due to favipiravir and to observe whether other drugs also produce fluorescence in the nail.
Methods: The research is descriptive, prospective, and quantitative.
The effect of vitamin C supplementation on favipiravir-induced oxidative stress and proinflammatory damage in livers and kidneys of rats.
Immunopharmacol Immunotoxicol
October 2023
Department of Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
Favipiravir (FPV), an effective antiviral agent, is a drug used to treat influenza and COVID-19 by inhibiting the RNA-dependent RNA polymerase (RdRp) of RNA viruses. FPV has the potential to increase oxidative stress and organ damage. The purpose of this study was to demonstrate the oxidative stress and inflammation caused by FPV in the liver and kidneys of rats, as well as to investigate the curative effects of vitamin C (VitC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!